Wednesday, 20 Mar 2019

You are here

Baricitinib Effective in SLE Trial

Dan Wallace and colleagues report in Lancet the results of a phase II study of the selective baricitinib, an oral selective Janus kinase (JAK1 and JAK2) inhibitor, in patients with systemic lupus erythematosus (SLE), demonstrating the efficacy and safety of JAK1/2 inhibition with baricitinib as a new potential oral therapy for SLE.

This randomised, placebo-controlled, 24-week trial enrolled 314 active (with skin or joint involvement), ANA+ or dsDNA+ SLE patients from in 11 countries to receive daily baricitinib 2 mg, or baricitinib 4 mg, or placebo. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K).

At week 24, an SLEDAI-2K arthritis or rash response was seen in 67% of baricitinib 4 mg, 58% of baricitinib 2 mg and 53% of placebo patients (4mg vs PBO; p=0·0414).  The SRI-4 response was also significant for the Bari 4 mg cohort only.

Adverse events were similar between groups and similar to that seen with baricitinib in the rheumatoid arthritis trials. Serious adverse events were reported in ten (10%) patients receiving baricitinib 4 mg, 11 (10%) receiving baricitinib 2 mg, and five (5%) receiving placebo; no deaths were reported. Serious infections were reported in six (6%) patients with baricitinib 4 mg, two (2%) with baricitinib 2 mg, and one (1%) with placebo.

This trial demonstrates the potential use of higher dose baricitinib therapy in uncontrolled SLE patients. Further studies must be done before JAK inhibition could be used to treat problematic lupus not controlled on standard or approved therapies. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

The patients haven't had good response to DMARDs or they are naaive? How about increased risk of thrombosis with JAK inhibitors in SLE especially with positive anti phospholipid serology?

More Like This

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.

2018 Swedish Guidelines for Giant Cell Arteritis Treatment

The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab. 

Congenital Heart Block: Dangers Ahead

Children of autoantibody-positive mothers who were born with congenital heart block were at high risk for developing later cardiovascular and autoimmune disorders, as were their siblings, Swedish researchers reported.